2022
DOI: 10.1016/j.cell.2022.09.030
|View full text |Cite
|
Sign up to set email alerts
|

SYK coordinates neuroprotective microglial responses in neurodegenerative disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
94
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 126 publications
(120 citation statements)
references
References 81 publications
4
94
0
Order By: Relevance
“…In‐line with these findings, an independent study published alongside our paper similarly showed that SYK signalling in microglia is required to support efficient containment and disposal of Aβ in the 5xFAD mouse model of AD 10 . Both of our groups also revealed that boosting SYK activation can offer a robust strategy to enhance Aβ control in mouse models of AD 9,10 . More specifically, our collective studies demonstrated that activating the SYK‐associated receptor CLEC7A via injection with either anti‐CLEC7A antibodies or a natural, fungal‐derived CLEC7A ligand both offer effective interventions to limit amyloidosis in 5xFAD mice.…”
Section: Figuresupporting
confidence: 77%
See 1 more Smart Citation
“…In‐line with these findings, an independent study published alongside our paper similarly showed that SYK signalling in microglia is required to support efficient containment and disposal of Aβ in the 5xFAD mouse model of AD 10 . Both of our groups also revealed that boosting SYK activation can offer a robust strategy to enhance Aβ control in mouse models of AD 9,10 . More specifically, our collective studies demonstrated that activating the SYK‐associated receptor CLEC7A via injection with either anti‐CLEC7A antibodies or a natural, fungal‐derived CLEC7A ligand both offer effective interventions to limit amyloidosis in 5xFAD mice.…”
Section: Figuresupporting
confidence: 77%
“… 10 Both of our groups also revealed that boosting SYK activation can offer a robust strategy to enhance Aβ control in mouse models of AD. 9 , 10 More specifically, our collective studies demonstrated that activating the SYK‐associated receptor CLEC7A via injection with either anti‐CLEC7A antibodies or a natural, fungal‐derived CLEC7A ligand both offer effective interventions to limit amyloidosis in 5xFAD mice.…”
Section: Figurementioning
confidence: 96%
“…There was no such change in the expression of these genes in macrophage cluster 5. Instead, several genes were upregulated in the morphine group, including C-type lectin domain family 7 member A (CLEC7A), a myeloid-predominant pattern-recognition receptor implicated in protection from Alzheimer’s disease ( 99 , 100 ), type II major histocompatibility genes such as MAMU-DQA1, which are increased in macrophage activation ( 101 ), and the intermediate filament protein gene vimentin (VIM), which is increased in macrophages differentiation and activation ( 102 ). None of these genes had appreciable expression in the microglial clusters.…”
Section: Resultsmentioning
confidence: 99%
“…Perhaps mouse models that are aged and genetically manipulated to progressively develop Aβ plaques and tau tangles may provide better models for testing TREM2 therapeutics. Additional microglial activating receptors have also been pointed out by genetic and experimental studies as new drug candidates, such as TAM receptors and CLEC7A [158,211,212]. The development of all these approaches will help to design effective and individually tailored therapeutics for AD.…”
Section: Discussionmentioning
confidence: 99%